Latest Breaking News On - Venostent inc - Page 1 : comparemela.com

VenoStent Enrolls First Subjects in 200-Subject US Clinical Trial

VenoStent Enrolls First Subjects in 200-Subject US Clinical Trial

United statesGeoffrey lucksEric pedenHala barakatJenniferl horspoolTimothy boireJason burgessTim boireVenostent selfwrap bioabsorbable perivascularMark barakatClinical affairs mark barakatNews networkClinical affairsVenostent incNational science foundationBreakthrough technology

VenoStent Closes $16M Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesTim boireTexas halo fundVenostent incBaylor angel network affinity fundNational institute of healthHealth wildcattersVenture fundNational science foundationGood growth capitalBaylor angel networkAffinity fundCreative venturesCowtown angelsAlumni venturesNational institute

VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US Trial

VenoStent Completes $16M Series A Financing, Receives IDE Approval from FDA to Begin US Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJoel whitleyTim boireBob crutchfieldJenniferl horspoolHealth wildcattersVenture fundVenostent incNational science foundationDrug administrationNational institute of healthBaylor angel network affinity fundTexas halo fundInvestigational device exemptionBreakthrough designationGood growth capital

VenoStent Completes $16M Series A Financing, Receives IDE Approval

VenoStent Completes $16M Series A Financing, Receives IDE Approval .

United statesJoel whitleyJenniferl horspoolTim boireBob crutchfieldNews networkNational science foundationTexas halo fundNational institute of healthHealth wildcattersDrug administrationVenostent incVenture fundBaylor angel network affinity fundStent completesInvestigational device exemption

VenoStent Technology Receives Breakthrough Device Designation by FDA

Designation to promote more rapid Agency and market access for VenoStentHOUSTON, TX / ACCESSWIRE / May 17, 2022 / VenoStent, Inc., a clinical-stage tissue engineering company developing bioabsorbable perivascular

United statesVenostent selfwrapKostenloser wertpapierhandelTim boireJennifer horspoolBreakthrough devices programCenters for medicare medicaid servicesRadiological healthDrug administrationVenostent incBioabsorbable perivascular wrapBreakthrough device designationTransitional pass through paymentTransitional add on paymentMedicaid services